Summary
The relative mortality from cardiovascular disease is on average increased five-fold in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy compared to non-diabetic subjects. We assessed the possible contribution of dyslipidaemia in general and elevated serum apolipoprotein(a) (apo(a)) in particular. Type 2 diabetic patients with normo-, micro- and macroalbuminuria were compared with healthy subjects. Each group consisted of 37 subjects matched for age, sex and diabetes duration. Serum creatinine in the nephropathy group was 105 (54–740) Μmol/l. The prevalence of ischaemic heart disease (resting ECG, Minnesota, Rating Scale) was 57, 35, 19 and 2% in macro-, micro- and normoalbuminuric diabetic patients and healthy subjects, respectively. The prevalence of ischaemic heart disease was higher in all diabetic groups as compared to healthy subjects (p<0.05), and higher in macroalbuminuric as compared to normoalbuminuric diabetic patients (p<0.01). There was no significant difference between apo(a) in the four groups: 161 (10–1370), 191 (10–2080), 147 (10–942), 102 (10–1440) U/l (median (range)) in macro-, micro- and normoalbuminuric groups and healthy subjects. Serum total-cholesterol, HDL-cholesterol and LDL-cholesterol were not significantly different when comparing healthy subjects and each diabetic group. Apolipoprotein A-I was lower (p<0.05) in all diabetic groups as compared to healthy subjects (nephropathy vs healthy subjects): 1.50±0.25 vs 1.69±0.32 g/l (mean ± SD). Triglyceride was higher (p<0.05) in patients with nephropathy and microalbuminuria as compared to healthy subjects (nephropathy vs healthy subjects): 2.01 (0.66–14.7) vs 1.09 (0.41–2.75) mmol/l (median (range)). Apolipoprotein B was higher (p<0.02) in patients with nephropathy as compared to the other three groups (nephropathy vs healthy subjects): 1.54±0.47 vs 1.33±0.30 g/l. In conclusion, our case-control study has confirmed that Type 2 diabetic patients with increased urinary albumin excretion frequently suffer from dyslipidaemia and cardiovascular disease. However, our study revealed no significant elevation in serum concentration of apo(a) in patients with diabetic nephropathy, but numbers were small.
Article PDF
Similar content being viewed by others
References
Koistinen MJ (1990) Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. Br Med J 301: 92–95
Gall M-A, Rossing P, SkØtt P et al. (1991) Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 655–661
Nelson RG, Pettitt DJ, Carraher M-J, Baird HR, Knowler WC (1988) Effect of proteinuria on mortality in NIDDM. Diabetes 37: 1499–1504
Utermann G (1989) The mysteries of lipoprotein(a). Science 246: 904–910
Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H (1990) Lipoprotein(a) and coronary heart disease: a prospective case-control study in general population sample of middle aged men. Br Med J 301: 1248–1251
Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL (1986) Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 256: 2540–2544
Berg K, Dahlen G, Frick MH (1974) Lp(a) lipoprotein and pre-Β 1-lipoprotein in patients with coronary heart disease. Clin Genet 6: 230–235
Wiklund O, Angelin B, Olofsson S-O et al. (1990) Apolipoprotein(a) and ischaemic heart disease in familial hypercholeste-rolaemia. Lancet 335: 1360–1363
Hasstedt SJ, Williams RR (1986) Three alleles for quantitative Lp(a). Genet Epidemiol 3: 53–55 (Letter)
Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U (1989) Detection and quantification of lipoprotein(a) in arterial wall of 107 coronary bypass patients. Arteriosclerosis 9: 579–592
Parving H-H, Gall M-A, SkØtt P et al. (1992) Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41: 758–762
Hother-Nielsen O, Faber O, SØrensen NS, Beck-Nielsen H (1988) Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables. Diabetes Care 11: 531–537
Faber OK, Binder C (1977) C-peptide response to glucagon: test for the residual Β-cell function in diabetes mellitus. Diabetes 26: 605–610
Wiinberg N, Nygardt J, SengelØv H, Nielsen PE (1988) Oscillometric measurement of the blood pressure. Ugeskr laeger 150: 1282–1284
Katterman R, Jaworek D, Möller G (1984) Multicenter study of a new enzymatic method of cholesterol determination. J Clin Chem Biochem 22: 245–251
Friedewald WT, Levy RI, Frederickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 18: 499–502
Goldstein DE, Peth SB, England JD, Hess RL, Randall LH, DaCosta J (1980) Effects of acute changes in blood glucose on HbA1c. Diabetes 29: 623–628
Andersen I, Hannibal S (1983) Analytical and economical optimization of a glucose method with immobilized enzymes. J Automatic Chemistry 4: 188–192
Ullmann R, Bonitz K (1976) Vollmechanisierte kinetische Messung von Kreatinin. Med Labor Bd 29: 137–145
Christensen C, Ørskov C (1984) Rapid screening PEG radioimmunoassay for quantification of pathological microalbuminuria. Diabetic Nephropathy 3: 92–94
Blackburn H, Keys A, Simonson E, Rautaharju P, Punsar S (1960) The electrocardiogram in population studies: a classification system. Circulation 21: 1160–1175
Rose GA, Blackburn H (1968) Cardiovascular survey methods. WHO Monograph Series No. 56: 162–165
Schernthaner G, Kostner GM, Dieplinger H, Prager R, Mühlhauser I (1983) Apolipoproteins (A-I, A-Il, B) Lp(a), lipoprotein and lecithin: cholesterol acetyltransferase activity in diabetes mellitus. Arteriosclerosis 49: 277–293
Ruotolo G, Zoppo A, Parlavecchia M, Giberti B, Micossi P (1991) Apolipoprotein(a) levels in type 1 and type 2 diabetes mellitus. Acta Diab 28: 158–161
Guillausseau P-J, Peynet J, Chanson P et al. (1992) Lipoprotein(a) in diabetic patients with and without chronic renal failure. Diabetes Care 15: 976–979
Kostner G, Klein G, Krempler F (1984) Can serum lipoprotein Lp(a) concentrations be lowered by drugs and/or diet? In: Carlsson LA, Olsson AG (eds) Treatment of hyperlipoproteinaemia. Raven Press, New York, pp 151–156
Haffner SM, Morales PA, Stern MP, Gruber MK (1992) Lp(a) concentrations in NIDDM. Diabetes 41: 1267–1272
Jenkins AJ, Steel JS, Janus ED, Santamaria JD, Best JD (1992) Plasma apolipoprotein(a) is increased in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 35: 1055–1059
Emancipator K (1992) Low bias in assayed values of lipoprotein antigens-lipoprotein(a) and apolipoprotein A-1 and B- in midday postprandial blood specimens compared with morning fasting specimens. Clin Chem 38: 431–433
Kapelrud H, Bangstad H-J, Dahl-JØrgensen K, Berg K, Hanssen KF (1991) Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. Br Med J 303: 675–678
Jenkins AJ, Steele JS, Janus ED, Best JD (1991) Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 40: 787–790
Gall M-A, Rossing P, Hommel E et al. (1992) Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. J Clin Lab Invest 52: 513–521
Winocour PH, Bhatnagar D, Ishola M, Arrol S, Durrington PN (1991) Lipoprotein(a) and microvascular disease in type 1 (insulin-dependent) diabetes. Diabetic Med 8: 922–927
O'Donnell MJ, Bain SC, Barnett AH, Jones A (1991) Lp(a) concentrations. Br Med J 303: 1134 (Letter)
Karádi I, Romics L, Pálos G et al. (1989) Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 35: 2121–2123
Cressman MD, Hoff HF, Nally JV Jr, Schreiber M Jr, Van Lente F (1991) Lipoprotein(a) and the cardiovascular risk of end stage renal disease. J Am Soc Nephrol 234 (Abstract)
Black IW, Wilcken DE (1992) Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. Clin Chem 38: 353–357
Orchard T, Usher D, Maser R, Stein E, Manderino A (1992) Does Lp(a) relate to complications of IDDM? The Pittsburg epidemiology of diabetes complications study (EDC). Diabetes 41: 31A (Abstract)
Haffner SM, Moss SE, Klein BEK, Klein R (1992) Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin epidemiologic study of diabetic retinopathy. Metabolism 41: 194–197
Carlsson LA, Hamten A, Asplund A (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226: 271–276
Noma A, Meada S, Okuno M, Abe A, Muto Y (1990) Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with α-tocopheryl nicotinate. Arteriosclerosis 84: 213–217
Thiery J, Armstrong VW, Schleef J, Creutzfeldt C, Creutzfeldt W, Siedel D (1988) Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochenschr 66: 462–463
Betteridge DJ (1989) Lipids, diabetes, and vascular disease: the time to act. Diabetic Med 6: 195–218
Wiedmann P, Beretta-Piccoli C, Keusch G et al. (1979) Sodium-volume factor, cardiovascular reactivity and hypotensive mechanism of diuretic therapy in mild hypertension associated with diabetes mellitus. Am J Med 67: 779–784
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nielsen, F.S., Voldsgaard, A.I., Gall, M.A. et al. Apolipoprotein(a) and cardiovascular disease in Type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia 36, 438–444 (1993). https://doi.org/10.1007/BF00402281
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00402281